BESPAK
LIVE

Serial Number

98420336

Owner

Bespak Europe Limited

Attorney

Shannon Marie McKeon

Filing Date

Feb 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BESPAK Trademark

Serial Number: 98420336

BESPAK is a trademark filed by Bespak Europe Limited on February 26, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Bespak Europe Limited (2 trademarks)

Bergen Way North Lynn Industrial Estate
Norfolk PE302JJ , GB

Entity Type: 24

Trademark Details

Filing Date

February 26, 2024

Registration Date

Not Registered

Goods & Services

Provision of training, teaching and educational services in the nature of workshops, lectures, classes and tutorials, all in the field of manufacturing, engineering, chemistry and pharmaceuticals; training services in the field of injection molding manufacturing; advisory, consultancy and information services relating to all the aforesaid

Custom manufacture of medical devices for others; custom manufacture of medical devices to the order and specification of others, namely, inhalers and drug delivery devices sold empty, and pharmaceuticals; custom manufacture of components, parts and fittings for all the aforesaid products; management of product lifecycles for others, in the nature of custom manufacturing of medical devices to the order and specification of others, namely, inhalers and drug delivery devices sold empty, and pharmaceuticals; custom manufacturing of injection molded parts for others; custom manufacture of active pharmaceutical ingredients for others; custom manufacture of pharmaceuticals for others

Pharmaceutical preparations and substances for the treatment of infectious, viral, bacterial, metabolic, endocrine, exocrine, muscular, skeletal, cardiovascular, respiratory, reproductive, digestive, excretory, renal, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, lymphatic, integumentary, nervous, hormonal, dermatological, psychiatric and immunological related diseases and disorders; Pharmaceutical products, namely, respiratory drugs for treating respiratory diseases and asthma; respiratory vaccines

Drug delivery devices sold empty, namely, nasal inhalers for medical purposes, sold empty; pressurised metered dose inhalers (pMDI) for medical purposes, sold empty; nasal sprays for medical purposes; soft mist inhalers for medical purposes, sold empty; parts and fittings for all the aforesaid goods

Research and development of medical apparatus and instruments for others; research and development of inhalers and design of prototyping services; metrology services; Research laboratory testing and analysis services in the field of prototyping, metrology, manufacturing, engineering, chemistry, medical and pharmaceuticals; product quality testing services; quality control advisory services namely regulatory quality control advisory of pharmaceuticals, active pharmaceuticals ingredients, medical apparatus and instruments, inhalers and drug delivery products, pharma and medical related products and apparatus and management of product lifecycles for others, namely, continuing scientific research in the nature of conducting and managing clinical trials and trials of medical apparatus and instruments, inhalers and drug delivery products, pharma and medical related products and apparatus; consulting services in the field of pharmaceutical research and development; consulting services in the field of drug delivery devices; advisory, consultancy and information services relating to all the foresaid

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 2, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 2, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 2, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 2, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 2, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 22, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 16, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 16, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 16, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 2, 2024 NWOS
NEW APPLICATION ENTERED
Feb 26, 2024 NWAP